# A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants

> **NCT02268864** · PHASE2 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 106 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Simeprevir
- **DRUG:** Daclatasvir

## Key facts

- **NCT ID:** NCT02268864
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2016-01
- **Final completion:** 2016-04
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2017-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268864, "A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02268864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*